Morgan Stanley Maintains Equal-Weight on Genmab, Lowers Price Target to $56
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.